Related Experiment Video
Updated: Apr 15, 2026

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
Published on: February 10, 2023
Cardiovascular pharmacotherapy: Innovation stuck in translation
Gerard A Rongen1, Kimberley E Wever2
1Department of Pharmacology-Toxicology and Internal Medicine, Radboud university medical center, P.O. box 9101, Internal post address: 137, 6500 HB Nijmegen, The Netherlands.
Abstract:
Systematic reviews of animal studies have revealed serious limitations in internal and external validity strongly affecting the reliability of this research. In addition inter-species differences are likely to further limit the predictive value of animal research for the efficacy and tolerability of new drugs in humans. Important changes in the research process are needed to allow efficient translation of preclinical discoveries to the clinic, including improvements in the laboratory and publication practices involving animal research and early incorporation of human proof-of-concept studies to optimize the interpretation of animal data for its predictive value for humans and the design of clinical trials.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease V: Interprofessional Care
Pharmacogenomics: Identification of New Drug Targets
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Cardiopulmonary Resuscitation IV: Pharmacological Management

